Pharmaceuticals Global On demand · 24-48h

Global Dotinurad Tablets Market Strategic Research Report

Global Dotinurad Tablets Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Dotinurad Tablets Market
$70.432025
15.6%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: 0.5mg per Tablet, 1.0mg per Tablet, 2.0mg per Tablet

By Application: Hyperuricaemia, Gout, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Fuji Yakuhin, Mochida Pharmaceutical, Eisai, Ziska Pharmaceutical, General Pharmaceuticals

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 83 pages
Market size 2025
$70.43
Million USD
Forecast CAGR
15.6%
2025-2032
Forecast 2032
$194.3
Projected
영역들
5
Asia Pacific · Latin America · MEA · Europe · North America

개요

Scope of the Report

The global Dotinurad Tablets market size is predicted to grow from US$ 70.43 million in 2025 to US$ 190 million in 2032; it is expected to grow at a CAGR of 15.6% from 2026 to 2032.

Dotinurad tablets belong to a class of medications known as selective uric acid reabsorption inhibitors.They are primarily prescribed for the treatment of hyperuricemia associated with gout.By blocking URAT1,Dotinurad increases the excretion of uric acid in the urine,thereby lowering blood uric acid levels and reducing the risk of urate crystal formation in joints and tissues.

Dotinurad is a first-in-class Selective Urate Reabsorption Inhibitor (SURI) that lowers serum uric acid levels by selectively inhibiting the URAT1 transporter in the renal proximal tubule, enhancing uric acid excretion. Developed by Eisai, it was first approved in Japan in 2020 and subsequently received marketing authorization in China in December 2024 under the brand name Urelice®. Compared to xanthine oxidase inhibitors like allopurinol and febuxostat, Dotinurad offers a differentiated safety and efficacy profile, particularly in patients with renal dysfunction or intolerance to XOIs. With over 10 million gout patients in China and limited treatment penetration, Dotinurad addresses a significant unmet clinical need. Its novel mechanism, favorable tolerability, and strategic positioning as the first SURI approved in China highlight its strong commercial potential and licensing value in the evolving urate-lowering therapy landscape.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Dotinurad Tablets market?

What factors are driving Dotinurad Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Dotinurad Tablets market opportunities vary by end market size?

How does Dotinurad Tablets break out by Type, by Application?

This report presents a comprehensive overview of the global Dotinurad Tablets market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • 0.5mg per Tablet
  • 1.0mg per Tablet
  • 2.0mg per Tablet

Segment by Technology

  • Original Drug
  • Generic Drug

Segment by Application

  • Hyperuricaemia
  • Gout
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Dotinurad Tablets market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Hyperuricaemia, Gout, Other evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Dotinurad Tablets Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 15.6%
Regional growth momentum
Market share by segment
Key metrics
Base value
$70.43
2025
Forecast
$194.3
2032
CAGR
15.6%
2025–2032
영역들
5
global
Key companies
Fuji YakuhinMochida PharmaceuticalEisaiZiska PharmaceuticalGeneral Pharmaceuticals
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
0.5mg per Tablet1.0mg per Tablet2.0mg per Tablet
By Application
HyperuricaemiaGoutOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 0.5mg per Tablet
  • 3.1.3 1.0mg per Tablet
  • 3.1.4 2.0mg per Tablet
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Hyperuricaemia
  • 4.1.3 Gout
  • 4.1.4 Other
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Fuji Yakuhin
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Mochida Pharmaceutical
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Eisai
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Ziska Pharmaceutical
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 General Pharmaceuticals
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Dotinurad Tablets market?
The global Dotinurad Tablets market is estimated at US$ 70.43 million in 2025 (base year) and is projected to reach US$ 190 million by 2032.
What is the forecast CAGR for the Dotinurad Tablets market?
The market is expected to grow at a CAGR of 15.6% from 2026 to 2032, expanding from US$ 70.43 million in 2025 to US$ 190 million in 2032, roughly 2.7 times its base-year value.
What is Dotinurad Tablets?
Dotinurad tablets belong to a class of medications known as selective uric acid reabsorption inhibitors.They are primarily prescribed for the treatment of hyperuricemia associated with gout.By blocking URAT1,Dotinurad increases the excretion of uric acid in the urine,thereby lowering blood uric acid levels and reducing the risk of urate crystal formation in joints and tissues.
What are the main segments of the Dotinurad Tablets market by type?
By type, the market is segmented into 0.5mg per Tablet, 1.0mg per Tablet and 2.0mg per Tablet.
Which applications drive demand in the Dotinurad Tablets market?
Key applications covered include Hyperuricaemia, Gout and Other.
Who are the key players in the Dotinurad Tablets market?
Key players profiled include Fuji Yakuhin, Mochida Pharmaceutical, Eisai, Ziska Pharmaceutical and General Pharmaceuticals.
Which regions and countries are covered for Dotinurad Tablets?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Dotinurad Tablets market?
What factors are driving Dotinurad Tablets market growth, globally and by region?
Who should buy the Dotinurad Tablets market report?
The report is intended for manufacturers and solution providers, distributors and end users in Hyperuricaemia, Gout and Other, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Dotinurad Tablets market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from US$3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.